drugset / Trial / NCT05536297
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
Timeline
- Start
- 2022-09-26
- Primary completion
- 2025-04-10
- Completion
- 2025-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacincaptad Pegol | Aptamer | 2 mg | Intravitreal |